Skip to main content
Premium Trial:

Request an Annual Quote

Atugen, Schering Pen Gene-Function Deal

NEW YORK, Sept. 17 - Atugen said today that Schering has chosen it to help perform drug-target and gene-function studies.

 

The one-year agreement calls for Atugen to develop antisense oligonucleotides that inhibit the expression of certain undisclosed drug targets picked by Schering. The two German companies will then analyze the oligos, called GeneBlocs, in the hopes of validating gene function and disease association, the partners said.

 

The deal comes on the heals of a five-year drug target-validation collaboration that ends this year between Atugen, Schering, and Schering's US-based research group Berlex Biosciences.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.